Research · Sep 3, 2026
[TGTX] TG Therapeutics Thesis 2026: An Anti-CD20 MS Drug Scales Toward Profitability and a CAR-T Optionality Pipeline
TG Therapeutics, Inc. (NASDAQ: TGTX) is a Morrisville, North Carolina-headquartered commercial-stage biopharmaceutical company that, after a decade-long, often-contentious development path, achieved a transformative success with the December 2022 FDA approval of BRIUMVI (ublituximab) — an anti-CD20 monoclonal antibody — for relapsing forms of multiple sclerosis in adults. The company traces back to the 2012 formation of TG Therapeutics by Michael S. Weiss (a former investment banker and biopharma investor) and an earlier reverse-merger with Manhattan Pharmaceuticals. For most of the 2010s and early 2020s, TG was a small clinical-stage company developing ublituximab and other assets (initially in oncology — chronic lymphocytic leukemia / CLL — under the rationale that the next-generation glycoengineered anti-CD20 antibody would compete with Roche's Rituxan/rituximab) and trading on the binary outcomes of those programs; the CLL/oncology path had setbacks (a complete response letter and a withdrawn US oncology BLA in 2023 over methodology concerns), but MS — pivoted to in the late 2010s — delivered the ULTIMATE I & II Phase 3 trials that supported the December 2022 BRIUMVI approval, followed by EU approval in 2023. BRIUMVI launched in early 2023 and has ramped rapidly into a multi-billion-dollar relapsing-MS market. Behind BRIUMVI, TG holds an autoimmune-CAR-T optionality position via the 2023 acquisition of azer-cel (an allogeneic CD19 CAR-T cell therapy) from Precision BioSciences (DTIL) for use in lupus, anti-Synthetase Syndrome and other autoimmune indications, plus a BTK inhibitor (TG-1701) and earlier-stage molecules. Geography is US-led commercialization with growing European and select ex-EU launches. The capital structure has flipped from years of dilution to a path of self-funded growth. TGTX enters FY2026 with FY2025 net product revenue selected various aggregate ~$500-700M (entirely BRIUMVI; rapid growth from $292M in 2024), aggregate adjusted EPS ~$0.10-0.70 (flipped to profitability), gross margin ~95%+ (biologic), operating cash flow positive and growing, under President & CEO Michael S. Weiss (~10+ year tenure). The first thesis pillar is BRIUMVI: a glycoengineered anti-CD20 monoclonal antibody engineered for enhanced ADCC that depletes B cells (a key driver of MS pathology), administered as a 1-hour IV infusion every six months after an initial loading dose; the clinical rationale being that the B-cell-depletion class (Roche's Ocrevus, Novartis's Kesimpta) has revolutionized relapsing-MS treatment over the past decade by significantly outperforming traditional first-line therapies on relapse-rate and disability-progression endpoints, becoming first-line standard of care; BRIUMVI's differentiation: shorter infusion time (1 hour vs Ocrevus's ~3.5-hour first / ~2-hour subsequent), glycoengineered design (potentially more potent), competitive pricing (launch-list price modestly below Ocrevus, supporting payer access and Buy & Bill economics); the launch — US BRIUMVI launched January 2023 and has ramped faster than initial Street expectations, with net product revenue from ~$8M in 1Q23 → ~$50M in 4Q23 → ~$100M+/quarter by 2024 year-end → toward ~$130-180M+/quarter in 2025 (a clearly steepening curve), driven by payer access (commercial + Medicare formularies), Buy-and-Bill economics for infusion-administering neurology practices, switch dynamics from oral DMTs and earlier-generation IV agents, and Ocrevus-naive new starts; FY2025 dynamics are revenue growing ~$100M+/quarter sequentially, payer broadening, infusion-center capacity adding, gross-to-net stabilizing, operating costs growing slower than revenue, and the company moving through breakeven; FY2026 catalyst is continued US revenue growth (toward ~$700M-1.0B+ annual run-rate), ex-US ramp (EU launches underway), the subcutaneous BRIUMVI Phase 3 (would dramatically expand the addressable population by enabling at-home dosing, matching Kesimpta and competing with Ocrevus Zunovo SC), label expansion, and operating leverage; risks/competitors are Roche's Ocrevus (entrenched leader, Ocrevus Zunovo SC launched 2024), Novartis's Kesimpta (SC anti-CD20), BTK inhibitors (Sanofi's tolebrutinib, Roche's fenebrutinib — emerging class), oral DMTs (Tecfidera, Mavenclad, Mayzent, Vumerity), pricing/payer pressure, and SC BRIUMVI execution. The second pillar is the pipeline plus commercial-infrastructure optionality: azer-cel (azercabtagene zapreleucel) — an allogeneic ('off-the-shelf') CD19 CAR-T cell therapy acquired from Precision BioSciences (DTIL) in late 2023, originally for B-cell malignancies but now being repurposed by TG for B-cell-driven autoimmune diseases — principally systemic lupus erythematosus (SLE), lupus nephritis, anti-Synthetase Syndrome — where autologous CAR-T has shown striking early-phase signals (deep B-cell depletion → drug-free remissions in small Phase 1 studies from academic groups and competitors like Cabaletta (CABA) and Kyverna (KYTX)); azer-cel's allogeneic design could provide scale/economics advantages if clinical data hold (lower cost, off-the-shelf, no apheresis); TG-1701 (oral, brain-penetrant BTK inhibitor in earlier-stage development for autoimmune/oncology); the commercial infrastructure as a platform (US specialty neurology salesforce + payer/reimbursement org — asset-light way to in-license additional autoimmune or MS-adjacent products); FY2025 dynamics are azer-cel autoimmune trial initiation, early academic-data crosstalk in lupus, TG-1701 progression; FY2026 catalyst is azer-cel clinical data (any early efficacy signals would be transformative), TG-1701 data, possible in-licensing/partnerships; risks/competitors are azer-cel clinical failure (allogeneic CAR-Ts have had mixed clinical success vs autologous — durability/persistence concerns), competing autoimmune CAR-T programs (Cabaletta (CABA), Kyverna (KYTX), Bristol-Myers's Breyanzi exploration, Novartis's Kymriah, plus T-cell engagers), the broader autoimmune market (rituximab, anti-CD19 inebilizumab/Uplizna, JAK inhibitors), and TG's first cell-therapy execution. The capital story: no dividend, no buybacks of consequence (cash to BRIUMVI commercialization, ex-US launch, azer-cel development, capital strength), cash/equivalents/short-term investments ~$300-500M+ (bolstered by improving OCF as BRIUMVI revenue scales — TG flipped to operating-profit positive during 2024 and is on a trajectory of self-funded growth), modest convertible debt ~$120-160M nominal (manageable, conversion price relevant for dilution math), no material term loans, net debt near zero or net-cash, ~155-165M shares (heavy historical dilution from years of equity financings, but issuance pace dramatically slowed as cash builds), with the trajectory of operating cash flow vs operating-cost base, convertible-debt dilution dynamics, cash-allocation on azer-cel/in-licensing, and the historical share-count creep (now stabilizing) as the principal considerations — a future buyback would be a meaningful confidence signal; a dividend remains unlikely near-term. At ~$25-45 per share on ~155-165M shares (~$4-7B equity, EV broadly similar) TGTX prices an increasingly real BRIUMVI franchise (the multi-quarter trajectory toward $1B+ annual revenue) plus optionality on azer-cel and the broader pipeline; on EV/sales ~6-12x against FY2025 revenue, justified-by-bulls by the growth rate and the path to mid-teens-or-higher P/E once profitability scales — versus comp groups: MS — Biogen (BIIB), Sanofi (SNY, tolebrutinib in MS), Novartis (NVS, Kesimpta), Roche (Ocrevus), Bristol-Myers (BMY, Zeposia); commercial-stage neurology/specialty biopharma — Vertex (VRTX), Argenx (ARGX, Vyvgart), Apellis (APLS), Insmed (INSM), Krystal Biotech (KRYS); autoimmune-CAR-T — Cabaletta Bio (CABA), Kyverna Therapeutics (KYTX). FY2026 base case: ~$700M-1.0B+ revenue + ~$0.50-1.20 adj. EPS + continued US BRIUMVI growth + EU launch ramping + azer-cel data starting + self-funded growth + cash building + SC BRIUMVI Phase 3 progressing — scaling profitability; bull case: ~$1.0-1.4B+ revenue + ~$1.50-2.50+ adj. EPS on stronger BRIUMVI growth (SC formulation approved and launched, ex-US accelerating, BTK delays in MS leaving room for anti-CD20s), azer-cel autoimmune data positive (a major asymmetric upside), pipeline expansion, FCF inflection, an eventual buyback, and a re-rating; bear case: ~$450-650M revenue + ~$(0.10)-0.30 adj. EPS on Ocrevus Zunovo SC + Kesimpta intensifying competitive pressure, US share losses, ex-US disappointment, azer-cel failing in autoimmune trials, SC BRIUMVI slipping or competing poorly, and a de-rating. The thesis depends on the BRIUMVI commercial pipeline (US prescription growth + ex-US ramp + subcutaneous formulation + payer/Buy-and-Bill dynamics + share dynamics in the B-cell-depletion class) plus the pipeline-and-commercial-optionality pipeline (azer-cel autoimmune CAR-T + TG-1701 BTK + the platform for in-licensing) plus operating leverage to profitability plus a defensive cash position plus Michael Weiss's continued execution of the BRIUMVI commercial and pipeline-expansion playbook.